Clinical and biochemical features of sporadic and hereditary phaeochromocytomas: An analysis of 41 cases investigated in a single endocrine centre

European Journal of Cancer Prevention

Volumn 13, Issue 5, 2004, Pages 403-409

  Patocs A ^a   Karadi E ^a   Toth M ^a   Varga, I ^b   Szucs N ^a   Balogh, K ^a   Majnik, J ^a   Glaz E ^a   Racz K ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Catecholamine; Phaeochromocytoma; RET protooncogene; VHL gene

Indexed keywords

CATECHOLAMINE; PROTEIN RET; VON HIPPEL LINDAU PROTEIN;

ADRENAL TUMOR; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; DIASTOLIC BLOOD PRESSURE; FAMILIAL CANCER; FAMILY; FEMALE; FOLLOW UP; GENE; GENE MUTATION; GENETIC SCREENING; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; MALE; NEUROFIBROMATOSIS; PHEOCHROMOCYTOMA; PREVALENCE; PRIORITY JOURNAL; PROTO ONCOGENE; RET GENE; SIPPLE SYNDROME; SYSTOLIC BLOOD PRESSURE; VHL GENE; VON HIPPEL LINDAU DISEASE;

ADRENAL GLAND NEOPLASMS; ADULT; AGE FACTORS; BLOOD PRESSURE; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; PHEOCHROMOCYTOMA; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 5044238401     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008469-200410000-00008     Document Type: Article

References (38)

1. Astuti D, Latif F, Dallol A, et al. (2001). Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial phaeochromocytoma and to familial paragangioma. Am J Hum Genet 69: 49-54.
2. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. (2000). Mutations in SDHD, a mitochondrial complex gene, in hereditary paraganglioma. Science 287: 848-851.
3. Benn DE, Croxson MS, Tucker K, et al. (2003). Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas. Oncogene 22: 1358-1364.
4. Berndt I, Reuter M, Saller B, et al. (1998). A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 83: 770-774.
5. Brandi ML, Gagel RF, Angeli A, et al. (2001). Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86: 5658-5671.
6. Bravo EL (2002). Pheochromocytoma. Cardiol Rev 10: 44-50.
7. Chen F, Kishida T, Yao M, et al. (1995). Germline mutations in the von Hippel-Lindau disease tumour suppressor gene: correlations with phenotype. Hum Mutat 5: 66-75.
8. Crossey PA, Richards FM, Foster K, et al. (1994). Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet 3: 1303-1308.
9. Eisenhofer G, McClellan MW, Huynh T-T, et al. (2001). Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab 86: 1999-2008.
10. Elchisak MA, Carlson JA (1982). Assay of free and conjugated catecholamines by high-performance liquid chromatography with electrochemical detection. J Chromatogr 233: 79-88.
11. Gerlo EAM, Sevens C (1994). Urinary and plasma catecholamines and urinary catecholamine metabolites in phaeochromocytoma: diagnostic value in 19 cases. Clin Chem 40: 250-256.
12. Gimm O, Armanios M, Dziema H, et al. (2000). Somatic and occult germline mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma, Cancer Res 60: 6822-6825.
13. Hes FJ, Höppener JWM, Lips CJM (2003). Pheochromocytoma in von Hippel-Lindau disease. J Clin Endocrinol Metab 88: 969-974.
14. Hjemdahl P, Daleskog M, Kahan T (1979). Determination of plasma catecholamines by high performance liquid chromatography with electrochemical detection: comparison with a radioenzymatic method. Life Sci 25: 131-138.
15. Hull CJ (1986). Phaeochromocytoma: diagnosis, pre-operative preparation, and anaesthetic management. Br J Anaesth 58: 1453-1468.
16. Ito Y, Fujimoto Y, Obara T (1992). The role of epinephrine, norepinephrine, and dopamine in blood pressure disturbances in patients with pheochromocytoma. World J Surg 16: 759-763.
17. Januszevicz A, Neumann HPA, Lon I, et al. (2000). Incidence and clinical relevance of RET proto-oncogene germline mutations in pheochromocytoma patients. J Hypertension 18: 1019-1023.
18. Kalff V, Shapiro B, Lloyd R, et al. (1982). The spectrum of pheochromocytoma in hypertensive patients with neurofibromatosis. Arch Intern Med 142: 2092-2098.
19. Koch CA, Vortmeyer AO, Zhuang Z, et al. (2002). New insights into the genetics of familial chromaffin cell tumors. Ann N Y Acad Sci 970: 11-28.
20. Latif F, Tory K, Gnarra J, et al. (1993). Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260: 1317-1320.
21. Levine C, Skimming J, Levine E (1992). Familial pheochromocytomas with unusual associations. J Pediatr Surg 27: 447-451.
22. Luton JP, Martinez M, Coste J, et al. (2000). Outcome of patients with adrenal incidentaloma selected for surgery: an analysis of 88 cases investigated in a single clinical center. Eur J Endocrinol 143: 111-117.
23. Manger WM, Gifford RW Jr (1995.) Pheochromocytoma: a clinical overview. In: Laragh JH, Brenner BM (editors): Hypertension: Pathophysiology, Diagnosis and Management, 2nd edn, New York: Raven Press; pp. 2225-2244.
24. Mannelli M, Ianni L, Cilotti A, et al. (1999). Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol 141: 619-624.
25. Medeiros LJ, Wolf BC, Balogh K, et al. (1985). Adrenal pheochromocytoma: a clinicopathologic review of 60 cases. Hum Pathol 16: 580-589.
26. Mulligan LM, Ponder BAJ (1995). Genetic basis of endocrine disease: multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 80: 1989-1995.
27. Neumann HPH, Bausch B, McWhinney SR, et al. (2002). Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346: 1459-1466.
28. Niemann S, Muller U (2000). Mutations in SDHC cause autosomal dominant paraganglioma type 3. Nat Genet 26: 268-270.
29. Page LB, Raker JW, Berberick FR (1969). Pheochromocytoma with predominant epinephrine secretion. Am J Med 47: 149-154.
30. Parmer RJ, Zinder O (2002). Catecholaminerg pathways, chromaffin cells, and human disease. Ann N Y Acad Sci 971: 497-505.
31. Pastore YD, Jelinek J, Ang S, et al. (2003). Mutations of the VHL gene in sporadic apparently congenital polycythemia. Blood 101: 1591-1595.
32. Patócs A, Valkusz Z, Igaz P, et al. (2003). Segregation of the V804L mutation and S836S polymorphism of exon 14 of the RET gene in an extended kindred with familial medullary thyroid cancer. Clin Genet 63: 219-223.
33. Pomares FJ, Canas R, Rodriguez JM, et al. (1998). Differences between sporadic and multiple endocrine neoplasia type 2A pheochromocytoma. Clin Endocrinol 48: 195-200.
34. Proye C, Fossati P, Fontaine P, et al. (1986). Dopamine-secreting phaeochromocytoma: an unrecognized entity? Classification of phaeochromocytomas according to their type of secretion. Surgery 100: 1154-1162.
35. Prys-Roberts C (2000). Pheochromocytoma - recent progress in its management. Br J Anaesth 85: 44-57.
36. Riccardi VM (1991). Von Recklinghausen neurofibromatosis. N Engl J Med 305: 1617-1627.
37. Uchino S, Noguchi S, Adachi MT et al. (1996). Presymptomatic detection and treatment of gene carriers of multiple endocrine neoplasia families for germ-line mutations of the ret gene. Cancer Detect Prev 20(Suppl): S5.
38. van der Harst E, de Herder WW, de Krijger RR, et al. (2002). The value of plasma markers for the clinical behaviour of phaeochromocytomas. Eur J Endocrinol 147: 85-94.